Regeneron's deep pipeline of potentially successful drugs helps to offset competitive risks in other areas.
Get this delivered to your inbox, and more info about our products and services.
This darling of the Covid era has given back considerable gains in recent years, but it could be on the verge of a turnaround.
The investment bank upgraded the pharma stock to overweight from equal weight.
We are making a pharmaceutical position swap into Wednesday's relief rally.
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…
Biogen could see lower royalties for Ocrevus after its patent expires , but it has developed other medicines that will support…
Citi sees shares of Ligand Pharmaceuticals soaring another 46% on top of an already impressive year-to-date rally.
